Precise innovation, wisdom and humanities Bearing the 25th anniversary of ups and downs, the 2022 CSCO Annual Meeting was grandly opened in Beijing!

The 25th National Congress of Clinical Oncology and the 2022 Chinese Society of Clinical Oncology Annual Conference officially kicked off in Beijing today, and the conference was held in the form of "Academic Conference Week" in five places from November 5 to 12, 2022.

The theme of this year's CSCO conference is precision innovation, wisdom and humanities, and this conference will provide a broad academic exchange platform
for oncologists across the country with the latest perspective, content and form.

CSCO leadership message to CSCO 25th anniversary

Message from the older generation of CSCO leaders CSCO 25th anniversary

press conference 

Professor Jiang Zefei

At the press conference held on the morning of the 5th, Professor Jiang Zefei, vice chairman and secretary general of CSCO, presided over and introduced the leaders who participated in the conference: Professor Xu Ruihua, Chairman of CSCO and Sun Yat-sen University Cancer Prevention and Treatment Center, Academician Yu Jinming, President-elect of CSCO and President of Shandong Cancer Hospital, Fan Jia, Vice Chairman of CSCO, Academician of Zhongshan Hospital Affiliated to Fudan University, Chairman of CSCO Foundation and Professor Li Jin of Dongfang Hospital Affiliated to Tongji University, Professor Ma Jun, Chairman of the Supervisory Committee of CSCO, Harbin Institute of Hematology and Oncology, Vice Chairman of CSCO, Professor Qin Shukui, Jinling Hospital of Nanjing University of Chinese Medicine, former Chairman of CSCO, Professor Wu Yilong of Guangdong Provincial People's Hospital, Vice Chairman of CSCO, Cheng Ying, Vice Chairman of CSCO, Jilin Cancer Hospital Professor, Vice Chairman of CSCO, Professor Liang Houjie, First Affiliated Hospital of Army Medical University, Vice Chairman of CSCO, Professor Yin Yongmei of Jiangsu Provincial People's Hospital Maternal and Child Branch, Vice Chairman of CSCO, Professor
Wu Lingying, Cancer Hospital of Chinese Academy of Medical Sciences.
Offline CSCO leaders: Vice Chairman and Secretary General of CSCO, Professor Guo Jun of Peking University Cancer Hospital, Vice Chairman of CSCO, Professor Liang Jun of Peking University International Hospital, Vice Chairman of CSCO, Professor Wang Jie of Cancer Hospital of Chinese Academy of Medical Sciences, Vice Chairman of Foundation, Professor
Zhu Jun of Peking University Cancer Hospital.

Group photo of "online + offline" experts at the press conference

Professor Xu Ruihua first delivered a welcome speech and warmly welcomed
the experts, colleagues and media attending the conference.
Professor Xu said that the 2022 CSCO Annual Meeting was finally presented
in the form of "offline + online" under intense and orderly preparation.
Over the past 25 years, CSCO has been innovating, pioneering and enterprising, and has worked tirelessly to promote the development of anti-tumor causes, and has achieved fruitful results
.
In the past year, we have overcome difficulties to hold the 2022 Guide Meeting, BOC/BOA Conference and this year's CSCO Annual Meeting in the form of "online + offline", which will be close to the international frontier, enhance the development of the discipline, promote in-depth exchanges among all colleagues, and jointly promote the vigorous development
of oncology.

Professor Xu Ruihua

In the media question session, CSCO leaders answered media questions, Professor Ma Jun said that 2030 Healthy China pointed out that the 5-year survival rate of malignant tumors should be increased by 15%, and there is a long way to go, and only under the leadership of the Party and the government can CSCO play a better role
.
At present, CSCO has formulated guidelines for 39 tumor types, Professor Ma Jun said that CSCO has good communication with the Hospital Administration, the National Health Commission Capacity Building and Continuing Education Center, the International Exchange Center and other departments, in addition, CDE and the Medical Insurance Bureau will use the CSCO guidelines as the basis for diagnosis and treatment standards or included in the corresponding indications of medical insurance
.
Professor Ma Jun said that the ultimate goal of one medical government, one medicine, and one doctor and patient is to make Chinese cancer patients obtain a longer and higher clinical cure rate
.
CSCO will work tirelessly with the government to promote a healthy China by 2030 to achieve the goal
better and faster.

Professor Ma Jun

Professor Qin Shukui said that CSCO has been established for its 25th anniversary, and the reason why CSCO has carried out extensive international exchanges is mainly based on three aspects: first, the needs of the times, malignant tumors are a high incidence in the world, seriously threatening the life and health of all mankind; Second, under the leadership of the older generation of leaders, all members are sincerely united, work together and work together; Third, one of the five major tasks of CSCO is to strengthen international and domestic scientific and technological exchanges and cooperation, over the years, CSCO and international famous anti-tumor academic organizations including WHO, UICC, ASCO, ESMO, JSCO and so on have established close ties, while learning international progress, China will also formulate norms and guidelines in line with national conditions to promote the process of specialization, standardization and standardization in the field of anti-tumor
.
In addition, Chinese scholars have also continued to go international, showing Chinese wisdom and contribution
.
Professor Qin Shukui said that through our efforts, we have continuously improved the level of cancer prevention and treatment for the whole people, and helped healthy China and the global anti-cancer cause
.

Professor Qin Shukui

Academician Yu Jinming said that when it comes to the standardization of clinical diagnosis and treatment, CSCO is a leading academic organization in China in terms of guideline revision and update, and CSCO regularly holds standardized training
throughout the country.
In 2020, when the epidemic was most dangerous, Professor Ma Jun took the lead in giving a number of speeches in the field of blood lymphoma, and other branches also responded positively and achieved good results
.
In the field of clinical research, a number of CSCO experts carry international and domestic large-scale clinical research, and also train young experts, which will make CSCO pass on the torch, research results are also published in internationally renowned journals, and China's research, achievements and Chinese voice have been affirmed
by the international oncology field.
I believe that the future of CSCO will be better
.

Academician Yu Jinming

Academician Fan Jia said that in the past 40 years of national reform and opening up, our country's economic strength has been continuously enhanced, and its international status has been continuously improved, therefore, the country's investment in basic science, applied science and biomedical fields has been increasing, and the investment in the field of medicine, in the fields of basic, translational and clinical research has been increasing, and research results have been continuously produced, and the research concept has been continuously enhanced, and the translational research results in the field of oncology are particularly prominent
。 In recent years, enterprise drug research and development can also seize opportunities and key points early, and constantly develop new drugs, clinicians have also accumulated a lot of experience in carrying out clinical research, in addition, clinical research provides a stronger basis and scientificity for the formulation of guidelines that are in line with national conditions and international standards, and the cooperation of hospitals and enterprises has contributed to the development of clinical research
.

Academician Fan Jia

Professor Li Jin said that grassroots doctors and medical students and graduate students are the backbone of the future medical field and shoulder the important task
of future medical science development.
This year, the CSCO Foundation sponsored 200 grassroots doctors and medical students to attend the conference in order to provide them with standardized training
.
Professor Li Jin said that he hopes that medical students can develop good scientific research habits from the beginning of their careers, on the other hand, through such initiatives, medical students can establish close contact with CSCO during school, establish a relationship foundation, so that medical students can feel that CSCO is a good platform to help professional doctors become talents, and ultimately expect them to grow into leaders in anti-tumor career
.

Professor Li Jin

Opening Speech Session

Professor Jiang Zefei presided over the opening ceremony, and Professor Jiang pointed out that due to the epidemic, this year's CSCO conference was held in the form of academic week, and was held
in Beijing, Jinan, Harbin, Shanghai and Guangzhou "five places" + "eight days".
The development of CSCO is inseparable from the guidance of senior teachers, the support of colleagues and the care and support
of overseas partners.
Professor Jiang expressed his gratitude
to Martin J.
Murphy, President of ASCO, ESMO President and old friends of CSCO, and Professor DMedSc for their blessings on the occasion of CSCO's 25th anniversary.
Professor Jiang pointed out that with the successful conclusion of the 20th National Congress, it is believed that more scholars will appear on the academic stage of ASCO and ESMO, and I believe that international colleagues will also come to CSCO to further promote international cooperation
.

Professor Jiang Zefei

Professor Eric P.
Winer, the current president of ASCO, said that 3 years ago, ASCO and CSCO formalized and expanded the cooperation model for a simple reason: cancer knows no borders, and fighting cancer requires continuous innovation and global cooperation, which is the common aspiration
of ASCO and CSCO.
The CSCO Annual Meeting is a perfect showcase of the sharing
of knowledge and ideas between the two societies.

Professor Eric P.
Winer

Professor Solange Peters, the current president of ESMO, said that the medical resources we have established are limited, and the aging population, the outbreak of new diseases, sedentary lifestyles, environmental pollution, economic recession and even armed violence have brought great pressure to daily life, and as an oncology society, we must assume our responsibility to ensure that patients can receive quality medical services
.
It is very gratifying to see Chinese scholars meet again at this year's CSCO Annual Conference and take this opportunity to exchange and cooperate
with each other.

Professor Solange Peters

Professor Martin J.
Murphy, co-founder of the American Society for Translational Oncology, said it is a great honor to meet again today at the CSCO 25th Anniversary Annual Meeting, CSCO will continue to lead the continuous development of oncology for the benefit of cancer patients and their families, the new crown epidemic has given us a great impact, but also provided us with the opportunity to devote ourselves more lovingly and more to clinical and research work for a safer, healthier and fairer future for all mankind
.

Professor Martin J.
Murphy

Professor Xu Ruihua said in his speech at the opening ceremony that the 20th National Congress of the Communist Party of China just held has further clarified the strategic goals of China's development, clarified the tasks of building a healthy China, clarified the strategy of rejuvenating the country through science and education, and clarified the core position of scientific and technological innovation in the overall situation of China's modernization construction, which has very important guiding significance
for the prevention and treatment of clinical oncology.
According to the 2018 global cancer statistics, China's cancer incidence and death rate ranked first, China is diagnosed with cancer every day, CSCO should raise the cancer prevention and treatment to the height
of implementing the scientific and technological innovation strategy.

2022 is a bumper year for CSCO guidelines, with a total of 33 guidelines released/updated, of which 5 related guidelines such as endometrial cancer were released for the first time, of which 2 were named after non-tumor names
.
The CSCO series of guidelines has become an essential material
to guide clinical and patient services.
It is worth pointing out that more and more Chinese scholars' research results have become evidence-based evidence for CSCO guidelines, and the leadership of oncology in China has been continuously improved
.
In addition, the number of CSCO members reached a new high, with a net increase of 4,500 CSCO members
.
The total number of registered individual members of the society exceeded 40,000, and the number of
group members reached 163.
The smooth development of this CSCO academic annual meeting is due to the continuous development of leading research, continuous innovation and breakthroughs by experts and scholars in the field of oncology in China, and the fruitful results, as well as the strong support
of experts and people from all walks of life.

Professor Xu Ruihua

Conference presentation session

Professor Qin Shukui of Nanjing University of Chinese Medicine and Cancer Center of Jinling Hospital presided over the meeting
.

Professor Qin Shukui

Tian Zhigang, academician of the Chinese Academy of Engineering and University of Science and Technology of China, delivered a keynote report
on "Synthetic Immunology and NK Cell Therapy".
"Synthetic immunology" refers to the rational manipulation of immune responses and immunotherapy
for major diseases by combining basic immunology knowledge and synthetic biology technology.
Academician Tian Zhigang said that synthetic immune technology will determine the final winner of the immune cell therapy competition, and will cross the original stage of "rough trial and error" in immunology, transition from qualitative research to quantitative, controllable and engineered stage, and use logic loops, feedback switches, intelligent manipulation and other technologies to artificially create immune cells and immune molecules
.
In the future, CAR-NK may be equal to CAR-T in cell therapy and become the next generation of tumor immunotherapy treatment
.

Academician Tian Zhigang

Shen Hongbing, academician of the Chinese Academy of Engineering and the Chinese Center for Disease Control, delivered a keynote report
on "Clinical Medical Research in the Era of Big Data".
Clinical medical research is based on the diagnosis, treatment, prognosis and cause of disease
.
Clinical medical research has entered the era of big data, and the paradigm has undergone fundamental changes
.
Academician Shen Hongbing emphasized that the correct and reasonable use of clinical resources is of strategic significance
for improving the level and efficiency of clinical scientific research.
In terms of improving the level of clinical medical research, we should pay attention to clinical epidemiology and evidence-based medical research, take special disease cohorts as the goal, pay attention to real-world research, take clinical problems and translational application as the guide, strengthen the support of interdisciplinary platforms, and strengthen team building and teamwork
.
Academician Shen Hongbing said that in the era of big data, we should focus on breaking the traditional thinking mode, using innovative clinical medical research methods, and meeting new opportunities and challenges
.

Academician Shen Hongbing 

Award ceremony

Professor Guo Jun served as the host

Professor Liang Jun

Professor Guo Jun served as the officiator
of the award ceremony.
Professor Liang Jun was the guest of honor and announced the winners of the 2022 CSCO Clinical Oncology Outstanding Paper Award
.
A total of 1469 paper submissions were received at the 2022 CSCO Annual Conference, and a total of 1 first prize, 2 second prizes and 7 third prizes were selected by the China Clinical Oncology Excellent Paper Award Review Committee, and the list of winners is as follows:

First Prize: Randomized, double-blind, multi-center phase III ASTRUM-007 clinical trial conducted by Professor Huang Jing's team from Cancer Hospital of Chinese Academy of Medical Sciences;

Second Prize: Randomized, double-blind, parallel-controlled, multicenter phase III clinical study of HR070809 combined with 5-FU/LV in the treatment of advanced pancreatic cancer after failure of gemcitabine treatment conducted by Professor Qin Shukui's team, respectively, and the efficacy and safety of individualized starting dose maintenance therapy with niraparib for newly diagnosed advanced ovarian cancer conducted by the team of Professor Li Ning of Cancer Hospital of the Chinese Academy of Medical Sciences (PRIME study): double-blind, placebo-controlled, phase III trial;

Third Prize: 7 papers
including a multicenter, randomized, double-blind, placebo-controlled phase III clinical study and subgroup analysis results of Donafenib tablets in the treatment of locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer conducted by Professor Lin Yansong's team at Peking Union Medical College Hospital.

Academician Fan Jia and Academician Yu Jinming announced the 2022 CSCO Clinical Oncology Annual Achievement Award
.
Academician Fan Jia congratulated that Professor Xu Ruihua led 61 companies and teams from all over the country for 3 years to use PD-1 antibody combined with paclitaxel/cisplatin for the first-line treatment of advanced esophageal squamous cell carcinoma, which changed the dilemma of 20 years of no progress in the treatment of esophageal squamous cell carcinoma, benefiting tens of millions of esophageal cancer patients and families
。 The ESCORT-1st study published in JAMA is a key turning point in the treatment of esophageal squamous cell carcinoma, promoting major changes in the treatment pattern of esophageal cancer, fully demonstrating the leading role of Chinese researchers in the international field of oncology clinical research and giving China's voice
to the world.

Academician Fan Jia

Professor Xu Ruihua said that being able to receive the annual achievement award issued by the CSCO conference is a recognition and affirmation of individual and team work, and it is also an encouragement and expectation
for doing scientific research in the future, doing a good job in scientific research, and striving for greater progress.
There is no end to medical exploration
.
As a medical science and technology worker, we need to maintain a curiosity to explore the unknown, a courage to challenge authority, and a hard work and perseverance to break through ourselves, rise up and act, strive infinitely, and strive to serve the overall situation of medical and social development, so that research results can be further transformed, and more research results can be implemented to benefit more patients
.

Professor Xu Ruihua gave a wonderful report
on the topic of "Exploration of Improving the Efficacy of Gastrointestinal Tumor Immunotherapy".
Professor Xu Ruihua pointed out that immunotherapy has brought new options for tumor treatment, but esophageal cancer, gastric cancer and colorectal cancer are considered "cold tumors" due to lack of immune cells, and the effectiveness rate of immunotherapy is < 15%, so it is urgent to explore new strategies<b13> to improve the efficacy of gastrointestinal tumor immunotherapy 。 Professor Xu Ruihua took the three directions of precise screening of sensitive subtypes of immunotherapy, exploration of new strategies of immune combination therapy, new mechanisms of immune escape and drug transformation as the starting point, combined with the heavy results of REGOTORI, ESCORT-1st, JUPITER-06 and other research, summarized various attempts and discoveries to improve the efficacy of immunotherapy at this stage, provided new ideas for follow-up research design, and pointed out the direction for better application of immunotherapy in clinical practice
.

Professor Xu Ruihua

Conference presentation session

Professor Ma Jun served as the host of the first session

Professor Qin Shukui interpreted a randomized double-blind, multicenter phase III.
clinical study
of HR070803 combined with 5-FU/LV in the treatment of advanced pancreatic cancer after failure of gemcitabine treatment 。 A total of 298 Chinese patients, 96% of whom were patients with metastatic pancreatic cancer, were included in the study, and the results showed that the primary endpoint OS of HR070803 combined with 5-FU/LV was significantly better than that of the comfort group (7.
39 vs 4.
99 months, HR=0.
63, P=0.
0019), median PFS (4.
21 vs 1.
48 months, HR=0.
36, P<0.
0001) and TTF (2.
92 vs 1.
45 months, HR=).
0.
42, P <0.
0001) were significantly better than the placebo group, and the ORR was higher (12.
75% vs 0.
67%, P<0.
0001).
<b11> Professor Qin Shukui said that the study is a second-line advanced pancreatic cancer study focusing on Chinese patients, and has contributed to
the exploration of safe and effective drug treatment options that are more in line with Chinese pancreatic cancer patients.

Professor Qin Shukui

Professor Li Jin served as the moderator of the second session

Professor Huang Jing shared a randomized, double-blind, multicenter, phase III clinical study
of serplulimab combined with chemotherapy versus placebo plus chemotherapy in the first-line treatment of PD-L1-positive advanced esophageal squamous cell carcinoma.
A total of 550 patients were included in the study, and the main endpoints were PFS and OS
.
The results showed that in the whole population, the median PFS of serplulimab combined with chemotherapy and placebo combined chemotherapy group was 5.
8 months vs 5.
3 months (HR=0.
60, P<0.
0001), OS was 15.
3 months vs 11.
8 months (HR=0.
68, P=0.
0020).
In the PD-L1 CPS≥10 population, the median PFS of the two groups was 7.
1 months versus 5.
3 months (HR=0.
48, P<0.
0001) and OS was 18.
6 months vs 13.
9 months (HR=0.
59, P=0.
0082).
<b12> Professor Huang said that the study achieved double-endpoint efficacy results, and the protocol for ESCC has been accepted by the NMPA, which is expected to provide new treatment options
for this type of patients.

Professor Huang Jing

Professor Cheng Ying served as the host of the third session

Prof.
Yansong Lin interpreted the results
of the multicenter, randomized, double-blind phase III.
DIRECTION study and subgroup analysis of donafenib in the treatment of locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC).
Professor Lin Yansong said that the DIRECTION study is currently the largest number of patients with RAIR-DTC in China, confirming that donafenib can be used as a treatment option
for progressive RAIR-DTC.
The DIRECTION study included 191 patients
with locally advanced/metastatic RAIR-DTC.
The results showed that donafenib significantly prolonged IRC-mPFS compared with placebo (12.
9 months vs 6.
4 months, HR=0.
389, P<0.
0001).
<b13> In all subgroups, mPFS was superior to placebo in the donafenib group
.
Professor Lin pointed out that the relevant results of the study have been presented
at this year's ESMO conference and the international conference on the field of thyroid.
At present, OS data is still immature and needs further follow-up and exploration
.

Professor Lin Yansong

Professor Wu Yilong served as the host of the final session

Professor Wang Jie further interpreted the IMpower010 study and said that the study was the first phase III study
to achieve positive results using adjuvant immunotherapy after surgical resection and adjuvant chemotherapy in patients with early-stage non-small cell lung cancer.
Results showed that adjuvant atezolizumab reduced the risk of disease recurrence or death by 34%
in stage II-IIIA population with PD-L1 TC≥1%.
Based on this, atezolizumab will change the status quo
of early adjuvant therapy for patients in many countries, including China and the United States.
Professor Wang Jie said that the research of IMpower010 study has basically settled, for stage IIA-III patients, the data is basically stable, and the results of the follow-up mainly observing the whole group population and the stage IB population are worth looking forward to, in addition, biomarker analysis based on biomarkers is worth further exploration
.

Professor Wang Jie

Professor Wang Jie concluded that CSCO has gone through 25 years of ups and downs, and it is also a demonstration of the efforts of several generations of CSCO members, and the CSCO Annual Meeting has become an academic event no less than ASCO, in this academic feast, field experts and industry scholars exchange the latest research results, as well as the thoughts and clinical experience of the research process, is a very high participation of academic events
.
Professor Wang Jie reviewed and summarized the academic reports of the morning celebrities and thanked
everyone for their participation.
Looking forward to seeing more sharing, harvesting and participation
in the subsequent academic week.

25th Anniversary CSCO Annual Meeting, Exciting Continues.
.
.

In the 25th anniversary, this CSCO annual meeting focused on the clinical frontier of tumors, adding special sessions such as tumor big data, biliary tumors, tumor hyperthermia, ablation therapy, etc.
, and conducted special discussions
on smart medical care, tumor photodynamic therapy, radiation intervention, vascular targeting, tumor markers, immunotherapy, and integrated traditional Chinese and Western medicine.
The thematic forums involving various cancer types and interdisciplinary disciplines were fully launched, helping participants to accurately and deeply understand the new progress in various professional fields, trigger new thinking, and look forward to more exciting CSCO Annual Meeting for the 25th anniversary.
.
.